Study area | No. of animals in each trial | Day 8 | Day 14 | EC50 (µg/ml thiabendazole) | ||
---|---|---|---|---|---|---|
FECR (%) unpaireda | FECR (%) paireda | FECR (%) unpaireda | FECR (%) paireda | |||
Beleil | Control: n = 6 | 99.9 (98.7–100) | 99.9 (99.5–100) | 99.9 (98.8–100) | 99.9 (99.5–100) | 0.011b (0.009–0.014) |
Treated: n = 11 | ||||||
Kass | Control: n = 5 | 99.7 (95.8–100) | 99.7 (98.9–100) | 99.5 (84.1–100) | 99.5 (98.3–99.9) | 0.012b (0.005–0.028) |
Treated: n = 11 | ||||||
Nyala | Control: n = 10 | 95.2 (88.2–98.7) | 96 (93.4–98.2) | 93.7 (84.9–97.6) | 94.6 (92.6–96.8) | 0.032b (0.023–0.046) |
Treated: n = 20 | ||||||
Rehed Al-Birdi | Control: n = 10 | 91.3 (46.4–98.5) | 92.9 (91.8–94) | 89.7 (46.1–97.8) | 92 (90.9–93) | 0.034b (0.017–0.065) |
Treated: n = 20 | ||||||
Tulus | Control: n = 10 | 90.7 (49.8–98.8) | 90.9 (89.6–92.3) | 88.2 (54.0–98.4) | 88.5 (87.2–90.1) | 0.037b (0.025–0.057) 0.113c (0.036–0.356) |
Treated: n = 20 |